ASCO 2025 - Non-Small Cell Lung Cancer

Patient-Reported Outcomes Highlight Favorable Tolerability of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial

Patient-reported outcomes from the Beamion LUNG-1 trial showed sustained improvements in physical functioning and symptom burden, with low side effect severity, supporting zongertinib’s potential in advanced NSCLC. Read More ›

Videos

Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial

By Beth Sandy, MSN, CRNP, FAPO

ASCO 2025 - Non-Small Cell Lung Cancer

The SOHO-01 trial highlights the manageable safety and promising efficacy of sevabertinib (BAY 2927088) in patients with pretreated or untreated HER2-mutant NSCLC. Read More ›

Non-Small Cell Lung Cancer Coverage Brought to You By

ASCO 2025 - Non-Small Cell Lung Cancer